Recent findings demonstrated that DOPs inhibited MUC5AC expression, leading to amelioration of airway inflammation in a rat model of COPD as well as improvement of vital capacity in COPD patients [17]. Here, MUC5AC is linked to chronic obstructive pulmonary disease.